# EVOKE-03 (NCT05609968)

> Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)

No report yet. It can be ordered.

- Drugs tested: sacituzumab govitecan plus pembrolizumab
- Indication: first-line PD-L1 TPS ≥50% metastatic non-small-cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05609968
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Carcinoma, Non-Small-Cell Lung
- Interventions: Sacituzumab Govitecan; Pembrolizumab
- Enrollment: 614
- Primary outcome: Progression-Free Survival (PFS)
- Primary outcome: Overall Survival (OS)

## Indexed commentary on EVOKE-03 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 48
- Podcasts: 7
- YouTube: 6

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=evoke-03-nct05609968

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05609968", "email": "<work email>"}; the inbox owner confirms by the emailed link.